Coherus Oncology, Inc. (CHRS)
Coherus Oncology, Inc. is a biopharmaceutical company primarily focused on the research, development, and commercialization of cancer immunotherapies across the United States. The company's commercialized products include several biosimilar therapies. These comprise UDENYCA, a long-acting granulocyte-colony stimulating factor biosimilar to Neulasta; YUSIMRY, an equivalent to Humira, prescribed for inflammatory conditions like rheumatoid arthritis, psoriasis, and Crohn's disease, which are characterized by heightened tumor necrosis factor (TNF) production; and CIMERLI, a Lucentis biosimilar aimed at treating specific ophthalmic disorders such as neovascular age-related macular degeneration, macular edema, and diabetic retinopathy. Beyond its commercial products, Coherus maintains a robust pipeline of investigational immunotherapies. This includes LOQTORZI, a novel, next-generation programmed death receptor-1 (PD-1) inhibitor; Casdozokitug, a recombinant human immunoglobulin G1 (IgG1) monoclonal antibody designed to target interleukin 27; CHS-114, a highly specific human afucosylated IgG1 monoclonal antibody targeting a chemokine receptor prevalent on Treg cells in the tumor microenvironment (TME); CHS-1000, an anti-ILT4 monoclonal antibody aimed at solid tumors; and GSK4381562, an antibody engineered to target CD112R on tumor cells. To support its endeavors, the company has forged several strategic alliances. These encompass a co-development and commercialization pact with Junshi Biosciences for toripalimab, as well as agreements with Surface and Adimab LLC. Its licensing portfolio includes arrangements with Bioeq AG, Genentech, Inc., Surface, and Vaccinex, Inc. Furthermore, Coherus has out-licensing agreements with Novartis Institutes for Biomedical Research, Inc. and GlaxoSmithKline Intellectual Property No. 4 Limited. Founded in 2010, the company currently operates as Coherus BioSciences, Inc., but is slated to officially rebrand as Coherus Oncology, Inc. in May 2025. Its headquarters are located in Redwood City, California.
Sector: Biological Products, (No Diagnostic Substances)
Industry: Biotechnology
Coherus Oncology, Inc.
NASDAQ:CHRSHealthcare · Biotechnology
-7.60%$0.8301
AH$0.8420+1.43%vs close
Mkt Cap$128.25M
Float145.13M
O/S154.5M
Vol
$ Vol
RVOL
Inst Own45.3%
SI8.6%
Earnings
Dilution
Financials Summary
Revenue$42.17M
Net Income-$170.29M
Total Assets$258.34M
Free Cash Flow-$138.51M
Debt & Equity
Debt 40%
Equity 60%
Total Debt$40.34M
Total Equity$61.01M
Shares Outstanding
Short Interest
Split History
No splits on record
Nothing in CHRS's public trading history: no forward or reverse split has affected the share count.
Balance Sheet Details
Assets$258.34M
Liabilities$197.33M
Accounts Receivable$18.42M
Accounts Payable$9.91M
Inventory$3.17M
PP&E (Net)$1.34M
Goodwill$0
Intangible Assets$46.24M
Income Statement
| Period | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 | FY 2014 | FY 2013 | FY 2012 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Currency | USD | USD | USD | USD | USD | USD | USD | USD | USD | USD | USD | USD | USD | USD |
| Period Ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 | 2017-12-31 | 2016-12-31 | 2015-12-31 | 2014-12-31 | 2013-12-31 | 2012-12-31 |
| Revenue | $42.17M | $266.96M | $257.24M | $211.04M | $326.55M | $475.82M | $356.07M | $1.56M | $1.56M | $190.11M | $30.04M | $31.11M | $2.75M | $1.9M |
| YoY Growth | -84.2% | 3.8% | 21.9% | -35.4% | -31.4% | 33.6% | 22783.7% | 0.0% | -99.2% | 532.8% | -3.4% | 1030.7% | 44.9% | - |
| Cost of Revenue | $17.74M | $117.55M | $158.99M | $70.08M | $57.59M | $37.67M | $17.08M | $3.23M | $160.53M | $254.44M | $212.68M | $78.22M | $31.28M | $34.89M |
| Gross Profit | $24.43M | $149.41M | $98.25M | $140.96M | $268.96M | $438.16M | $338.99M | -$1.68M | -$158.97M | -$64.33M | -$182.64M | -$47.12M | -$28.53M | -$32.99M |
| Gross Margin | 57.9% | 56.0% | 38.2% | 66.8% | 82.4% | 92.1% | 95.2% | -107.9% | -10216.9% | -33.8% | -608.0% | -151.5% | -1037.0% | -1737.1% |
| Research and Development | $104.96M | $93.34M | $109.44M | $199.36M | $363.11M | $142.76M | $94.19M | $110.24M | $162.39M | $254.44M | $213.06M | $78.22M | $31.28M | $34.89M |
| Selling, General, and Administrative | $99M | $150.44M | $185.62M | $198.48M | $169.71M | $139.08M | $137.04M | $94.18M | $71.3M | $51.6M | $36.05M | $17.56M | $7.46M | $5.53M |
| Other | $0 | $17.3M | $6.4M | $0 | $0 | $0 | $0 | $4.69M | $3.4M | -$3.88M | -$4.84M | -$18.59M | -$12.35M | $7.01M |
| Total Operating Expenses | $203.97M | $261.07M | $301.45M | $397.84M | $532.82M | $281.84M | $231.22M | $204.42M | $233.69M | $306.04M | $249.11M | $95.79M | $38.74M | $40.42M |
| Operating Income (EBIT) | -$179.53M | -$111.67M | -$203.2M | -$256.88M | -$263.86M | $156.32M | $107.77M | -$204.42M | -$232.14M | -$115.93M | -$219.07M | -$64.68M | -$35.99M | -$38.52M |
| Operating Margin | -425.7% | -41.8% | -79.0% | -121.7% | -80.8% | 32.9% | 30.3% | -13137.3% | -14918.8% | -61.0% | -729.2% | -207.9% | -1308.4% | -2028.3% |
| Interest Expense | $9M | $27.16M | $40.54M | $32.47M | $22.96M | $21.17M | $17.6M | $9.68M | $9.55M | $7.98M | $33K | $3.9M | $5.29M | $1.51M |
| Interest Income | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Other Income (Expense) | -$3.59M | $140.17M | -$35.07M | -$34.87M | -$23.24M | -$20.61M | -$14.99M | -$4.99M | -$6.15M | -$11.86M | -$4.87M | -$22.5M | -$17.64M | $5.5M |
| Income Before Tax (EBT) | -$183.12M | $28.51M | -$238.27M | -$291.75M | -$287.1M | $135.71M | $92.78M | -$209.41M | -$238.29M | -$127.79M | -$223.94M | -$87.18M | -$53.63M | -$33.02M |
| Income Tax Expense | $0 | $0 | -$380K | $0 | $0 | $3.46M | $2.94M | $0 | $0 | $656K | $0 | $0 | $0 | $0 |
| Net Income | -$170.29M | $28.51M | -$237.89M | -$291.75M | -$287.1M | $132.24M | $89.83M | -$209.34M | -$238.17M | -$127.34M | -$223.26M | -$87.13M | -$53.63M | -$33.02M |
| Net Income Margin | -403.8% | 10.7% | -92.5% | -138.2% | -87.9% | 27.8% | 25.2% | -13453.7% | -15306.6% | -67.0% | -743.2% | -280.1% | -1949.7% | -1738.7% |
| Supplementary Data | ||||||||||||||
| EPS | -1.45 | 0.25 | -2.53 | -3.76 | -3.81 | 1.85 | 1.29 | -3.22 | -4.48 | -3.04 | -6.01 | -10.64 | -2.97 | -11.69 |
| Diluted EPS | -1.45 | 0.25 | -2.53 | -3.76 | -3.81 | 1.62 | 1.23 | -3.22 | -4.48 | -3.04 | -6.01 | -10.64 | -2.97 | -11.69 |
| Weighted Average OS | 120.37M | 114.55M | 94.16M | 77.63M | 75.45M | 71.41M | 69.68M | 65.01M | 53.13M | 41.91M | 37.12M | 8.19M | 18.08M | 2.83M |
| EBITDA | -$170.2M | $60.94M | -$193.94M | -$255.58M | -$260.69M | $159.76M | $111.03M | -$204.42M | -$225.34M | -$116.81M | -$222.04M | -$82.72M | -$47.94M | -$31.28M |
| EBITDA Margin | -403.6% | 22.8% | -75.4% | -121.1% | -79.8% | 33.6% | 31.2% | -13137.3% | -14481.7% | -61.4% | -739.1% | -265.9% | -1742.6% | -1647.3% |
Balance Sheet
| Period | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 | FY 2014 | FY 2013 | FY 2012 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Currency | USD | USD | USD | USD | USD | USD | USD | USD | USD | USD | USD | USD | USD | USD |
| Period Ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 | 2017-12-31 | 2016-12-31 | 2015-12-31 | 2014-12-31 | 2013-12-31 | 2012-12-31 |
| Assets | ||||||||||||||
| Current Assets | ||||||||||||||
| Cash and Cash Equivalents | $88.88M | $125.99M | $102.89M | $63.55M | $417.19M | $541.16M | $177.67M | $72.36M | $126.91M | $124.95M | $158.23M | $150.39M | $39.55M | $14.55M |
| Short-Term Investments | $83.25M | $0 | $14.86M | $128.13M | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Cash and Short-Term Investments | $172.13M | $125.99M | $117.75M | $191.68M | $417.19M | $541.16M | $177.67M | $72.36M | $126.91M | $124.95M | $158.23M | $150.39M | $39.55M | $14.55M |
| Accounts Receivable | $18.42M | $122.33M | $260.52M | $109.96M | $123.02M | $157.05M | $141.99M | $0 | $0 | $1.86M | $1.56M | $4.23M | $385K | $158K |
| Inventory | $3.17M | $70.09M | $62.6M | $38.79M | $37.64M | $44.23M | $9.81M | $1.66M | $0 | -$4.84M | -$4.36M | -$8.2M | $0 | $10.03M |
| Other Current Assets | $6.23M | $11.53M | $11.1M | $22.92M | $10.8M | $0 | $0 | $50K | $202K | $3.05M | $2.86M | $4.03M | $50K | $110K |
| Total Current Assets | $206.71M | $341.58M | $475.63M | $381.23M | $602.32M | $767.48M | $343.01M | $72.36M | $126.91M | $124.95M | $158.23M | $150.39M | $45.68M | $24.8M |
| Long-Term Assets | ||||||||||||||
| Property, Plant & Equipment Net | $1.34M | $2.84M | $5.12M | $8.75M | $7.81M | $10.11M | $16.49M | $6.66M | $12.77M | $10.77M | $10.5M | $4.47M | $1.74M | $1.6M |
| Goodwill | $0 | $0 | $943K | $943K | $943K | $943K | $943K | $943K | $943K | $943K | $943K | $943K | $0 | $0 |
| Intangible Assets | $46.24M | $53.65M | $70.73M | $4.99M | $2.62M | $2.62M | $2.62M | $2.62M | $2.62M | $2.62M | $2.62M | $2.62M | $0 | $0 |
| Long-Term Investments | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $785K | $785K | $785K | $785K | $0 | $0 | $0 |
| Deferred Tax Assets | $0 | $0 | $0 | $0 | $0 | $0 | $0 | -$785K | -$785K | -$785K | -$785K | $0 | $0 | $0 |
| Other Long-Term Assets | $4.05M | $50.47M | $77.18M | $84.93M | $65.64M | $60.5M | $45.87M | $16.89M | $19.36M | $39.2M | $40.09M | $28.79M | $27K | $129K |
| Total Long-Term Assets | $51.64M | $106.95M | $153.97M | $99.61M | $77.01M | $74.17M | $65.92M | $27.11M | $35.7M | $53.54M | $54.16M | $36.83M | $1.77M | $1.73M |
| Other Assets | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Total Assets | $258.34M | $448.53M | $629.6M | $480.85M | $679.33M | $841.65M | $408.93M | $99.47M | $162.61M | $178.49M | $212.38M | $187.22M | $47.45M | $26.53M |
| Liabilities | ||||||||||||||
| Current Liabilities | ||||||||||||||
| Accounts Payable | $9.91M | $28.46M | $35.22M | $11.53M | $16.16M | $15.2M | $25.98M | $15.29M | $15.71M | $20.58M | $29.5M | $10.8M | $3.69M | $3.9M |
| Short-Term Debt | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $4.2M | $1.74M |
| Current Income Tax Payable | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Current Unearned Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $8.82M | $1.96M | $50.95M | $23.99M | $14.28M | $2.02M |
| Other Current Liabilities | $16.07M | $33.11M | $21.52M | $22.61M | $22.01M | $22.24M | $20.61M | $419K | $3.63M | $26.89M | $20.91M | $37.55M | $25.82M | $3.13M |
| Total Current Liabilities | $141.88M | $282.98M | $331.77M | $138.69M | $165.33M | $145.65M | $114.97M | $33.26M | $28.39M | $56.38M | $106.02M | $51.78M | $53.7M | $11.25M |
| Long-Term Liabilities | ||||||||||||||
| Long-Term Debt | $37.05M | $264.93M | $473.37M | $471.06M | $408.28M | $404.02M | $178.39M | $103.09M | $101.61M | $100.26M | $0 | $0 | $0 | $0 |
| Long-Term Unearned Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $1.56M | $94.96M | $62.7M | $28.57M | $6.08M |
| Long-Term Deferred Tax Liabilities | $1.1M | $1.1M | $1.1M | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Other Long-Term Liabilities | $15.84M | $28.23M | $11.46M | $3.47M | $750K | $1.05M | $102K | $1.71M | $2.07M | $1.83M | $67.96M | $28.78M | $7.56M | $12K |
| Total Long-Term Liabilities | $55.45M | $297.54M | $491.26M | $479.57M | $416.28M | $415.02M | $188.74M | $138.06M | $132.08M | $159.13M | $219.31M | $120.46M | $36.13M | $6.09M |
| Other Liabilities | $0 | $0 | $0 | $0 | $0 | $0 | $0 | -$33.26M | -$28.39M | -$56.38M | -$106.02M | -$51.78M | $0 | $0 |
| Total Liabilities | $197.33M | $580.52M | $823.03M | $618.26M | $581.61M | $560.67M | $303.71M | $138.06M | $132.08M | $159.13M | $219.31M | $120.46M | $89.83M | $17.34M |
| Stockholders' Equity | ||||||||||||||
| Preferred Stock | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $54.7M | $54.7M |
| Common Stock | $12K | $12K | $11K | $8K | $7K | $7K | $7K | $7K | $6K | $5K | $4K | $3K | $1K | $1K |
| Retained Earnings | -$1.38B | -$1.55B | -$1.58B | -$1.34B | -$1.05B | -$762.75M | -$895M | -$984.83M | -$775.49M | -$537.32M | -$409.99M | -$186.72M | -$99.59M | -$45.96M |
| Comprehensive Income & Other | -$195K | -$275K | -$248K | -$249K | -$270K | -$270K | -$558K | -$282K | -$750K | -$630K | -$401K | -$525K | -$625K | -$226K |
| Other Stockholders' Equity | $1.44B | $1.42B | $1.39B | $1.2B | $1.15B | $1.04B | $1B | $946.23M | $806.02M | $556.67M | $403.05M | $253.48M | $57.21M | $55.15M |
| Total Equity | $61.01M | -$131.99M | -$193.43M | -$137.42M | $97.73M | $280.97M | $105.21M | -$38.59M | $30.54M | $19.35M | -$6.93M | $66.76M | -$42.38M | $9.19M |
| Minority Interest | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | -$1.29M | -$1.17M | -$722K | -$44K | $0 | $0 |
| Total Liabilities and Equity | $258.34M | $448.53M | $629.6M | $480.85M | $679.33M | $841.65M | $408.93M | $99.47M | $162.61M | $178.49M | $212.38M | $187.22M | $47.45M | $26.53M |
| Supplementary Data | ||||||||||||||
| Total Debt | $40.34M | $269.9M | $480.84M | $480.42M | $419.02M | $417.1M | $188.64M | $103.09M | $101.41M | $100.26M | $0 | $0 | $4.2M | $1.74M |
| Net Debt | -$48.54M | $143.92M | $377.95M | $416.88M | $1.83M | -$124.06M | $10.97M | $30.74M | -$25.5M | -$24.69M | -$158.23M | -$150.39M | -$35.35M | -$12.81M |
Cash Flow Statement
| Period | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 | FY 2014 | FY 2013 | FY 2012 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Currency | USD | USD | USD | USD | USD | USD | USD | USD | USD | USD | USD | USD | USD | USD |
| Period Ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 | 2017-12-31 | 2016-12-31 | 2015-12-31 | 2014-12-31 | 2013-12-31 | 2012-12-31 |
| Operating Activities | ||||||||||||||
| Net Income | $168.02M | $28.51M | -$237.89M | -$291.75M | -$287.1M | $132.24M | $89.83M | -$209.41M | -$238.29M | -$127.79M | -$223.94M | -$87.18M | -$53.63M | -$33.02M |
| Depreciation & Amortization | $3.92M | $5.28M | $3.79M | $3.7M | $3.45M | $2.89M | $3.26M | $3.23M | $3.4M | $3M | $1.87M | $674K | $404K | $221K |
| Deferred Income Tax | $0 | $0 | $0 | $0 | $9.44M | $0 | -$55K | $3.56M | $453K | -$1.31M | $1.68M | $13.85M | $12.32M | -$7.01M |
| Stock-Based Compensation | $16.97M | $27.8M | $43.11M | $50.74M | $51.36M | $38.16M | $33.59M | $34.8M | $36.06M | $27.42M | $16.72M | $11.06M | $2.04M | $443K |
| Changes in Working Capital: | ||||||||||||||
| Accounts Receivable | $93.56M | $149.35M | -$150.68M | $13.05M | $34.06M | -$15.22M | -$141.99M | $8.28M | $1.86M | -$299K | $857K | -$2.14M | -$120K | -$158K |
| Inventory | -$17.11M | -$31.95M | -$46.73M | -$47.35M | -$6.25M | -$38.36M | -$48.18M | -$5.48M | -$148K | $8.26M | -$1.27M | -$16.16M | -$384K | $122K |
| Accounts Payable | -$19.56M | -$3.94M | $23.76M | -$4.55M | $874K | -$9.82M | $9.89M | -$534K | -$4.45M | -$7.64M | $19.93M | $5.27M | -$386K | $3.38M |
| Other Working Capital | -$62.73M | -$57.57M | $136.83M | -$40.41M | $13.68M | $28.75M | $66.36M | $8.04M | -$2.39M | -$159.53M | $71.59M | $41.46M | $42.3M | $8.3M |
| Total Working Capital Change | -$5.84M | $55.89M | -$36.83M | -$79.26M | $42.36M | -$34.65M | -$113.93M | $10.3M | -$5.13M | -$159.21M | $91.11M | $28.43M | $41.41M | $11.64M |
| Other Non-Cash Items | -$321.58M | -$137.92M | $52.93M | $75.45M | $143.05M | $15.5M | $15.65M | -$1.75M | $3.22M | $5.35M | $4.56M | $9.23M | $12.87M | $9.47M |
| Net Cash from Operating | -$138.51M | -$20.44M | -$174.88M | -$241.12M | -$37.43M | $154.15M | $28.36M | -$159.27M | -$200.29M | -$252.54M | -$107.99M | -$23.93M | $15.42M | -$18.25M |
| Investing Activities | ||||||||||||||
| Capital Expenditures | $0 | $0 | -$286K | -$2.04M | -$1.29M | -$7.23M | -$12.9M | -$789K | -$4.57M | -$6.51M | -$6.16M | -$2.85M | -$373K | -$1.78M |
| Acquisitions | $0 | $0 | $845K | $0 | $1.29M | $0 | $1.66M | -$700K | $0 | $0 | $0 | $2.33M | $0 | $0 |
| Purchases of Investments | -$103.84M | $0 | -$19.51M | -$127.38M | -$182.49M | -$273.85M | -$20.23M | -$42.87M | -$74.34M | $0 | -$785K | $0 | $0 | $0 |
| Sales of Investments | $21.46M | $14.89M | $157.64M | $0 | $181.36M | $274M | $20.4M | $43.17M | $74.5M | $0 | $0 | $0 | $0 | $0 |
| Other Investing Activities | $457.46M | $215.43M | $5.95M | -$37.43M | -$137.29M | -$7.33M | -$1.66M | $301K | $156K | -$6.51M | -$785K | -$10K | $0 | -$40K |
| Net Cash from Investing | $375.09M | $230.32M | $144.64M | -$166.85M | -$138.41M | -$14.4M | -$12.73M | -$1.19M | -$4.42M | -$6.51M | -$6.95M | -$525K | -$373K | -$1.82M |
| Financing Activities | ||||||||||||||
| Debt Repaid | $233.19M | $223.41M | - | -$49.93M | $672K | -$222.16M | -$72.95M | - | - | - | - | - | - | - |
| Common Stock Issuance | $8.25M | $1.46M | $74.22M | $6.36M | $40.9M | $0 | $8.15M | $101.75M | $206.85M | $123.61M | $122.8M | $85.42M | $6K | $0 |
| Common Stock Repurchases | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | -$544K | $0 | $0 | -$2K | $0 | $0 |
| Dividends Paid | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Other Financing Activities | -$48.77M | $34.98M | -$4.62M | -$1.96M | $54.3M | $1.79M | $8.26M | $3.67M | $482K | $2.57M | -$111K | -$4.12M | $6K | $0 |
| Net Cash from Financing | -$273.7M | -$186.97M | $69.6M | $54.33M | $51.88M | $223.95M | $89.37M | $105.42M | $206.79M | $226.18M | $122.69M | $135.96M | $9.96M | $26.94M |
| Forex Effect | $0 | $0 | -$12K | $0 | $0 | $0 | -$276K | $468K | -$120K | -$398K | $84K | -$666K | $0 | $0 |
| Net Change in Cash | -$37.13M | $22.91M | $39.34M | -$353.65M | -$123.96M | $363.69M | $104.72M | -$54.56M | $1.96M | -$33.28M | $7.83M | $110.84M | $25.01M | $6.86M |
| Supplementary Data | ||||||||||||||
| Operating Cash Flow | -$138.51M | -$20.44M | -$174.88M | -$241.12M | -$37.43M | $154.15M | $28.36M | -$159.27M | -$200.29M | -$252.54M | -$107.99M | -$23.93M | $15.42M | -$18.25M |
| Capital Expenditure | $0 | $0 | -$286K | -$2.04M | -$1.29M | -$7.23M | -$12.9M | -$789K | -$4.57M | -$6.51M | -$6.16M | -$2.85M | -$373K | -$1.78M |
| Free Cash Flow | -$138.51M | -$20.44M | -$175.17M | -$243.16M | -$38.72M | $146.91M | $15.46M | -$160.06M | -$204.86M | -$259.06M | -$114.15M | -$26.78M | $15.05M | -$20.03M |
| Cash at Beginning | $126.25M | $103.34M | $63.55M | $417.63M | $541.6M | $177.91M | $73.19M | $127.76M | $124.95M | $158.23M | $150.39M | $39.55M | $14.55M | $7.68M |
| Cash at End | $89.12M | $126.25M | $102.89M | $63.99M | $417.63M | $541.6M | $177.91M | $73.19M | $126.91M | $124.95M | $158.23M | $150.39M | $39.55M | $14.55M |